Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis

Phase 1 Completed 53 enrolled UCB Celltech ARENSIA, Moldova · collab Comac Medical · collab MAC Clinical Research · collab Parexel · collab

RandomizedSingle-groupDouble-blindTreatment

Summary

A study of UCB4940 in subjects with psoriatic arthritis to evaluate the safety and body distribution of UCB4940 in those patients. Neither the patient nor the doctor will know the treatment group.

Timeline

Start: 2014-05
Primary completion: 2015-08
Completion: 2015-08

Publications

Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018 Apr;77(4):523-532. doi: 10.1136/annrheumdis-2017-212127. Epub 2017 Dec 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimekizumab	Monoclonal antibody	40 mg	Intravenous
Subject	Bimekizumab	Monoclonal antibody	80 mg	Intravenous
Subject	Bimekizumab	Monoclonal antibody	160 mg	Intravenous
Subject	Bimekizumab	Monoclonal antibody	320 mg	Intravenous

Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis

Summary

Timeline

Publications

Drugs

Indications